Accueil > Actualité
Actualite financiere : Actualite bourse

Novartis: new positive data for Cosentyx

( - Novartis announces new positive data in its Phase III Prevent trial, evaluating the efficacy and safety of Cosentyx (secukinumab) in patients with non-radiographic axial spondylitis (nr-axSpA).

The trial achieved its primary endpoint by showing, after 52 weeks, a clinically significant reduction in disease activity compared to placebo. It also demonstrated a sustained response and safety profile consistent with previous clinical trials.

This data adds to five years of clinical data supporting Cosentyx's long-term efficacy and safety in ankylosing spondylitis, psoriatic arthritis and psoriasis, Novartis said.

Copyright (c) 2019 All rights reserved.




Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.
Indices et cours différés d’au moins 15 mn | Cotations boursières fournies par ABC Bourse.